Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia

Clinical Colorectal Cancer

Volumn 3, Issue 1, 2003, Pages 47-53

  Tagore, Kuldeep S ^a   Lawson, Michael J ^b   Yucaitis, Joy A ^c   Gage, Rhonda ^b   Orr, Tashia ^b   Shuber, Anthony P ^c   Ross, Michael E ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c Exact Sciences Corporation   (United States)

Author keywords

APC gene; Apoptosis; DNA integrity assay; K ras; Microsatellite instability marker; P53; Screening

Indexed keywords

DNA; PROTEIN P53; TUMOR MARKER;

ADENOMATOUS POLYP; ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER RISK; CANCER SCREENING; CANCER STAGING; COLON POLYPOSIS; COLONOSCOPY; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; DYSPLASIA; EARLY CANCER; EARLY DIAGNOSIS; FECES ANALYSIS; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OCCULT BLOOD TEST; ONCOGENE K RAS; POPULATION RISK; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; VILLOUS ADENOMA; COLORECTAL TUMOR; DIAGNOSTIC PROCEDURE; EVALUATION; FECES; GENE TARGETING; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PHYSIOLOGY; TIME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FECES; FEMALE; GENE TARGETING; GENES, APC; GENES, P53; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0037872037     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2003.n.011     Document Type: Article

References (28)

1. American Cancer Society. Cancer Facts and Figures 2003. Atlanta: American Cancer Society, 2003.
2. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365-1371.
3. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343:1603-1607.
4. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472-1477.
5. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467-1471.
6. Singh GK, Miller BA, Hankey BF, et al. Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1988: part I - all cancers among men. J Natl Cancer Inst 2002; 94:904-915.
7. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993; 329:1977-1981.
8. U.S. Preventative Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 2002; 137:129-131.
9. Wender R. Barriers to screening for colorectal cancer. Gastrointest Endosc Clin N Am 2002; 12:145-170.
10. Ahlquist D, Skoletsky J, Boynton K, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119:1219-1227.
11. Traverso G, Shuber A, Levin B, et al. Detection of APC mutation in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346:311-320.
12. Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359:403-404.
13. Dong S, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93:858-865.
14. Brand R, Shuber A, Laken S, et al. Reliability of a stool DNA mutation specific assay for colorectal cancer. Gastroenterology 2002; 122:A479.
15. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
16. Institut Curie. La Science au Service de l'Homme; Apc and p53 databases. Available at: http://p53.curie.fr/. Accessed March 14, 2003.
17. Boynton KA, Summerhayes IC, Ahlquist DA, et al. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003 (In press).
18. Syvanen AC, Aalto-Setala K, Harju L, et al. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 1990; 8:684-692.
19. National Cancer Institute. Surveillance, Epidemiology, and End Results. Available at: http://seer.cancer.gov/statistics/index.htm. Accessed November 11, 2002.
20. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345:555-560.
21. Allison JE, Tekawa IS, Ranson LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334:155-160.
22. Levin TR, Palitz AM. Flexible sigmoidoscopy: an important screening option for average-risk individuals. Gastrointest Endosc Clin N Am 2002; 12:23-40.
23. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia: A prospective study using HemoQuant and Hemoccult. JAMA 1993; 269:1262-1267.
24. Church TR, Ederer F, Mandel JS. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test. J Natl Cancer Inst 1997; 89:1392-1393.
25. Lieberman DA, Weiss DG, Bong JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. VA Cooperative Study Group 380. N Engl J Med 2000; 343:162-168.
26. Lieberman DA, De Garmo PL, Fleischer DE, et al. Patterns of endoscopy use in the United States. Gastroenterology 2000; 118:619-624.
27. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000; 342:1149-1155.
28. Green RJ, Metlay JP, Propert K, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of intergroup 0089. Ann Intern Med 2002; 136:261-269.